GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (FRA:2O9) » Definitions » Valuation Rank

Renalytix (FRA:2O9) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Renalytix Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Renalytix Valuation Rank Related Terms

Thank you for viewing the detailed overview of Renalytix's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (FRA:2O9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (FRA:2O9) » Definitions » Valuation Rank
Comparable Companies
LSE:COG LSE:INHC LSE:FDBK LSE:TRLS LSE:IQAI AQSE:DXSP LSE:KOO LSE:INS VEEV GEHC TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY EVH TDOC HKSE:01833
Traded in Other Exchanges
RNLX:USA RTNXF:USA RENX:UK 2O9:Germany
Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Website
https://www.renalytix.com
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.